
FDA Grants Priority Review to Sevabertinib (BAY 2927088) for Treating HER2-Mutant Non-Small Cell Lung Cancer
Bayer’s Sevabertinib (BAY 2927088) Receives FDA Priority Review for HER2-Mutant Non-Small Cell Lung Cancer FDA Bayer has announced that its investigational compound, sevabertinib (BAY 2927088), has been granted Priority Review status by the U.S. Food and Drug Administration (FDA) for…